Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | CHIEF FINANCIAL OFFICER | February 23, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date February 23, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 114,181 |
Reported balance
After 2026-02-23 transaction · row 1
1 source rowRow 1 · 2026-02-23 · Sale · Disposed 4,949 · Balance 114,181 F1: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Trust | 5,000 |
Reported balance
Holding disclosure · report date 2026-02-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.
F2: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.
F3: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2026 Filed Feb 26, 2026 00:59 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 4,949 | $41.98 | $207,778.32 |
DisclosureSEC source: 0001872792-26-000004 · form4-02262026_120222.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,181 F1 · date: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2 · kind: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 01:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $42.74 | $0.00 |
DisclosureSEC source: 0001872792-26-000002 · form4-02062026_080209.xml · derivative · entry 3 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2036-02-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 01:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872792-26-000002 · form4-02062026_080209.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,130 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes 893 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 12, 2025. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 53,800 | $0.00 Strike: $29.18 | $0.00 |
DisclosureSEC source: 0001415889-25-004846 · form4-02202025_090254.xml · derivative · entry 3 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,800 Underlying: Class A Common Stock · 53,800 shares Expires 2035-02-17 F2 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 26,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004846 · form4-02202025_090254.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,237 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 99,828 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · derivative · entry 21 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,172 Underlying: Class A Common Stock · 99,828 shares Expires 2031-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 1/4 of 180,000 shares subject to the option vested on July 12, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6,965 | $40.06 | $278,997.01 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 20 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 5,000 F8 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $40.355, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,944 | $39.19 | $115,384.19 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 19 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 11,965 F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.75 to $39.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,112 | $38.22 | $118,949.98 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 18 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 14,909 F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.70 to $38.64, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 453 | $40.05 | $18,144.46 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 17 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse's IRA Disclosed balance after: 0 F8 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $40.355, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 203 | $39.20 | $7,956.99 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 16 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse's IRA Disclosed balance after: 453 F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.75 to $39.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 201 | $38.23 | $7,684.43 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 15 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse's IRA Disclosed balance after: 656 F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.70 to $38.64, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,505 | $40.06 | $60,285.79 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 14 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 0 F8 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $40.355, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 639 | $39.19 | $25,044.33 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 13 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 1,505 F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.75 to $39.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 672 | $38.22 | $25,685.86 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 12 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 2,144 F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.70 to $38.64, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 867 | $40.06 | $34,731.15 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 11 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for UTMA account Disclosed balance after: 0 F8 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $40.355, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F9 · ownership.nature: The shares were acquired through a custodial account established for an immediate family member of the Reporting Person pursuant to the Uniform Transfers to Minors Act, for which the Reporting Person serves as a custodian. F10 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 366 | $39.19 | $14,341.71 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 10 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for UTMA account Disclosed balance after: 867 F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.75 to $39.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F9 · ownership.nature: The shares were acquired through a custodial account established for an immediate family member of the Reporting Person pursuant to the Uniform Transfers to Minors Act, for which the Reporting Person serves as a custodian. F10 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 387 | $38.22 | $14,792.69 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 9 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As custodian for UTMA account Disclosed balance after: 1,233 F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.70 to $38.64, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F9 · ownership.nature: The shares were acquired through a custodial account established for an immediate family member of the Reporting Person pursuant to the Uniform Transfers to Minors Act, for which the Reporting Person serves as a custodian. F10 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 177 | $40.06 | $7,090.27 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 8 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Roth IRA Disclosed balance after: 0 F8 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $40.355, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 80 | $39.22 | $3,137.36 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 7 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Roth IRA Disclosed balance after: 177 F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.75 to $39.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 78 | $38.20 | $2,979.21 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 6 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Roth IRA Disclosed balance after: 257 F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.70 to $38.64, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 7,361 | $39.25 | $288,926.61 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 5 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,337 F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.075 to $39.35, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 11,648 | $38.13 | $444,080.00 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 4 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,698 F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.52, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,988 | $38.65 | $424,708.18 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 3 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,346 F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.25 to $39.225, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 69,831 | $40.05 | $2,796,801.38 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 2 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,334 F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.36, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 01:32 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 99,828 | $14.87 | $1,484,442.36 |
DisclosureSEC source: 0001415889-24-010473 · form4-04062024_010405.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,939 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2024. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:03 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 97,500 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001415889-24-001514 · form4-01182024_090121.xml · derivative · entry 6 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Class A Common Stock · 97,500 shares Expires 2034-01-15 F3 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on February 16, 2024, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:03 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001514 · form4-01182024_090121.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,683 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs vest, rounded to the nearest whole share, on each of February 20, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes 2,500 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 13, 2023. Read SEC document |
| December 20, 2023 Filed Apr 6, 2024 01:27 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GiftClass A Common Stock | 636 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010472 · form4-04062024_010432.xml · nonDerivative · entry 4 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 18,021 F1 · balance_after: Reflects the number of shares held directly at the time and after giving effect to the reported gift. Read SEC document |
| July 24, 2023 Filed Apr 6, 2024 01:27 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GiftClass A Common Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010472 · form4-04062024_010432.xml · nonDerivative · entry 5 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for UTMA account Disclosed balance after: 1,620 F4 · ownership.nature: The shares were acquired through a custodial account established for an immediate family member of the Reporting Person pursuant to the Uniform Transfers to Minors Act, for which the Reporting Person serves as a custodian. F5 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 24, 2023 Filed Apr 6, 2024 01:27 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GiftClass A Common Stock | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010472 · form4-04062024_010432.xml · nonDerivative · entry 3 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 18,657 F3 · balance_after: Reflects the number of shares held by the trust at the time and after giving effect to the reported gift. The number also reflects a purchase reported on a Form 4 filed on June 23, 2023. Read SEC document |
| June 23, 2023 Filed Jun 23, 2023 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 5,000 | $16.60 | $83,000.00 |
DisclosureSEC source: 0001209191-23-039323 · doc4.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 5,992 Read SEC document |
| March 14, 2023 Filed Apr 6, 2024 01:27 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GiftClass A Common Stock | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010472 · form4-04062024_010432.xml · nonDerivative · entry 2 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 15,277 F2 · balance_after: Reflects the number of shares held by the trust at the time and after giving effect to the reported gift. Read SEC document |
| March 14, 2023 Filed Apr 6, 2024 01:27 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GiftClass A Common Stock | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010472 · form4-04062024_010432.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,648 F1 · balance_after: Reflects the number of shares held directly at the time and after giving effect to the reported gift. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:10 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001209191-23-010523 · doc4.xml · derivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 200,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 15, 2023, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| February 06, 2023 Filed Feb 17, 2023 21:17 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 14,285 | $7.00 | $99,995.00 |
DisclosureSEC source: 0001209191-23-010583 · doc4a.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,933 F1 · date: The reporting person's original Form 4 contained a typographical error on the transaction date. F2 · shares: Shares purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 6, 2023. The purchase price is the offering price. F3 · balance_after: Includes 380 shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047164 · doc4.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,268 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under Issuer's 2021 Equity Incentive Plan. One-third of the RSUs vest on August 20, 2023, rounded to the nearest whole share, and the remaining RSUs vest on August 20, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 992 | $13.60 | $13,491.99 |
DisclosureSEC source: 0001209191-22-037401 · doc4.xml · nonDerivative · entry 4 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 992 F1 · price: These shares were purchased in multiple transactions for all of Reporting Person's indirect accounts on the reported date with prices ranging from $13.05 to $13.85, resulting in a weighted average price of $13.6008. Upon request, the Reporting Person will provide to Issuer, the Commission staff or a security holder of the Issuer the number of shares purchased and the purchase price for each separate transaction. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 857 | $13.60 | $11,655.89 |
DisclosureSEC source: 0001209191-22-037401 · doc4.xml · nonDerivative · entry 3 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse's IRA Disclosed balance after: 857 F1 · price: These shares were purchased in multiple transactions for all of Reporting Person's indirect accounts on the reported date with prices ranging from $13.05 to $13.85, resulting in a weighted average price of $13.6008. Upon request, the Reporting Person will provide to Issuer, the Commission staff or a security holder of the Issuer the number of shares purchased and the purchase price for each separate transaction. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 335 | $13.60 | $4,556.27 |
DisclosureSEC source: 0001209191-22-037401 · doc4.xml · nonDerivative · entry 2 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Roth IRA Disclosed balance after: 335 F1 · price: These shares were purchased in multiple transactions for all of Reporting Person's indirect accounts on the reported date with prices ranging from $13.05 to $13.85, resulting in a weighted average price of $13.6008. Upon request, the Reporting Person will provide to Issuer, the Commission staff or a security holder of the Issuer the number of shares purchased and the purchase price for each separate transaction. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 2,816 | $13.60 | $38,299.85 |
DisclosureSEC source: 0001209191-22-037401 · doc4.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 2,816 F1 · price: These shares were purchased in multiple transactions for all of Reporting Person's indirect accounts on the reported date with prices ranging from $13.05 to $13.85, resulting in a weighted average price of $13.6008. Upon request, the Reporting Person will provide to Issuer, the Commission staff or a security holder of the Issuer the number of shares purchased and the purchase price for each separate transaction. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:09 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $20.94 | $0.00 |
DisclosureSEC source: 0001209191-22-011215 · doc4.xml · derivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Class A Common Stock · 90,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 16, 2022, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| February 06, 2022 Filed Feb 8, 2023 21:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 14,285 | $7.00 | $99,995.00 |
DisclosureSEC source: 0001209191-23-007769 · doc4.xml · nonDerivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,933 F1 · shares: Shares purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 6, 2023. The purchase price is the offering price. F2 · balance_after: Includes 380 shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:22 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0001209191-21-046781 · doc4.xml · derivative · entry 1 Grant Sean · CIK 0001872792 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Class A Common Stock · 180,000 shares Expires 2031-07-12 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on July 12, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.